Pegasus Asset Management Inc. Buys New Holdings in Jazz Pharmaceuticals PLC $JAZZ

Pegasus Asset Management Inc. purchased a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the third quarter, Holdings Channel reports. The firm purchased 15,826 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,664,000.

A number of other large investors have also made changes to their positions in JAZZ. Bank of New York Mellon Corp increased its holdings in shares of Jazz Pharmaceuticals by 44.5% in the first quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock valued at $317,485,000 after purchasing an additional 517,514 shares during the last quarter. Bank of America Corp DE boosted its stake in Jazz Pharmaceuticals by 10.9% during the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock worth $191,848,000 after buying an additional 99,656 shares during the last quarter. Systematic Financial Management LP boosted its stake in Jazz Pharmaceuticals by 2.6% during the first quarter. Systematic Financial Management LP now owns 407,114 shares of the specialty pharmaceutical company’s stock worth $76,965,000 after buying an additional 10,237 shares during the last quarter. Quantinno Capital Management LP grew its holdings in Jazz Pharmaceuticals by 9.7% in the 1st quarter. Quantinno Capital Management LP now owns 191,286 shares of the specialty pharmaceutical company’s stock valued at $36,163,000 after buying an additional 16,928 shares in the last quarter. Finally, Tri Locum Partners LP purchased a new stake in Jazz Pharmaceuticals in the 1st quarter valued at $29,995,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Robert Iannone sold 76,921 shares of the firm’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $249.70, for a total transaction of $19,207,173.70. Following the completion of the sale, the executive vice president directly owned 65,686 shares of the company’s stock, valued at approximately $16,401,794.20. This trade represents a 53.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Patricia Carr sold 1,413 shares of the business’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $231.36, for a total transaction of $326,911.68. Following the completion of the sale, the chief accounting officer owned 6,512 shares in the company, valued at approximately $1,506,616.32. This trade represents a 17.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 102,534 shares of company stock worth $25,185,243. Corporate insiders own 4.10% of the company’s stock.

Analysts Set New Price Targets

JAZZ has been the subject of a number of recent research reports. UBS Group raised their target price on Jazz Pharmaceuticals from $315.00 to $337.00 and gave the stock a “buy” rating in a research note on Friday, September 11th. Barclays boosted their price target on shares of Jazz Pharmaceuticals from $271.00 to $275.00 and gave the company an “overweight” rating in a research report on Tuesday, November 3rd. Robert W. Baird upped their price objective on shares of Jazz Pharmaceuticals from $252.00 to $280.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Stifel Nicolaus set a $275.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, August 4th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Jazz Pharmaceuticals from $300.00 to $310.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $293.45.

Jazz Pharmaceuticals News Summary

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
• Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage

Jazz Pharmaceuticals Trading Up 3.3%

JAZZ opened at $234.76 on Friday. Jazz Pharmaceuticals PLC has a one year low of $128.80 and a one year high of $266.38. The stock has a market capitalization of $15.07 billion, a PE ratio of 79.85, a P/E/G ratio of 0.44 and a beta of 0.38. The business’s 50 day moving average price is $229.39 and its 200 day moving average price is $217.74. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.58 and a current ratio of 1.82.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.03) by $0.15. Jazz Pharmaceuticals had a return on equity of 16.88% and a net margin of 4.37%. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same quarter last year, the firm earned $8.13 earnings per share. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. As a group, equities research analysts expect that Jazz Pharmaceuticals PLC will post 11.08 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets.

Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Jazz expanded its portfolio through acquisitions, including the 2021 acquisition of GW Pharmaceuticals, which added Epidiolex and other cannabinoid-based medicines.